Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Riad Abès"'
Autor:
Anne Marie-Cardine, Armand Bensussan, Laurent Gorvel, Daniel Olive, Arnaud Foussat, Jemila Houacine, Aude Le Roy, Jérôme Giustiniani, Riad Abes, Anne-Sophie Chrétien, Stéphane Fattori
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d4079860efaa49d18cf81970e80158fa
Autor:
Jean-Luc Teillaud, Riad Abès
Publikováno v:
Pharmaceuticals, Vol 3, Iss 1, Pp 146-157 (2010)
Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. These IgG sugar cores play a critical role in a number of IgG effector functions. In the pre
Externí odkaz:
https://doaj.org/article/ba6de702c1f5425ea44ea1c55b973c38
Autor:
Nicolas Poirier, Irène Baccelli, Lyssia Belarif, Riad Abès, Géraldine Teppaz, Caroline Mary, Sonia Poli, Claudia Fromond, Isabelle Girault, Sabrina Pengam, Emilienne Soma, Fanny De Sa, Jean-Pascal Conduzorgues, Cécile Braudeau, Regis Josien, Bram Volckaert, Dominique Costantini, Frédérique Corallo
Publikováno v:
The Journal of Immunology. 210:753-763
OSE-127 is a humanized mAb targeting the IL-7Rα-chain (CD127), under development for inflammatory and autoimmune disease treatment. It is a strict antagonist of the IL-7R pathway, is not internalized by target cells, and is noncytotoxic. In this wor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ccbcfdd76529608f0e743c281d891f2
https://doi.org/10.4049/jimmunol.2200635
https://doi.org/10.4049/jimmunol.2200635
Publikováno v:
Blood. 116:926-934
The anti-CD20 monoclonal antibody (mAb) rituximab has been used successfully for lymphoma therapy for more than 10 years. Although several direct mechanisms by which anti-CD20 mAbs act have been characterized in vitro, their specific role in clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b8096314c8b5030b3c803d471e6be12
https://doi.org/10.1182/blood-2009-10-248609
https://doi.org/10.1182/blood-2009-10-248609
Publikováno v:
médecine/sciences. 25:1011-1019
L’utilisation therapeutique des anticorps monoclonaux connait une croissance exponentielle. Nos connaissances sur leur structure, en particulier celle des IgG1 largement utilisees en therapeutique, se sont considerablement accrues. Cependant, de no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5d084b419694e02699877900dfeb7cd
https://doi.org/10.1051/medsci/200925121011
https://doi.org/10.1051/medsci/200925121011
Autor:
Riad Abès, Jean-Luc Teillaud
Publikováno v:
Cancer metastasis reviews. 30(1)
The surveillance of tumors by the immune system of cancer patients and its impact on disease progression and patient survival have been largely documented over the last years. In parallel, the use of therapeutic monoclonal antibodies (mAbs) in oncolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95fc1ea099a2b8486d1925b1a19fa222
https://pubmed.ncbi.nlm.nih.gov/21267767
https://pubmed.ncbi.nlm.nih.gov/21267767
Publikováno v:
Expert review of clinical immunology. 5(6)
Membrane Fcgamma receptors (FcgammaRs) can act either as potent activators of effector cell functions or as inhibitors of receptor-mediated cell activation following engagement by IgG antibodies bound to their target molecules. The remarkable ability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c360e3acd9cd227414dc90af27fd7730
https://pubmed.ncbi.nlm.nih.gov/20477693
https://pubmed.ncbi.nlm.nih.gov/20477693
Autor:
Jean-Luc Teillaud, Mariana Rodriguez-Zubieta, Marina Colombo, Gabriela Andrea Pizzurro, Riad Abès, Maria Marcela Barrio, Charlotte Boix, José Mordoh, María Paula Roberti, Emmanuelle Gélizé
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e40311 (2012)
PLoS ONE
PLoS ONE
Dendritic cells (DC) can achieve cross-presentation of naturally-occurring tumor-associated antigens after phagocytosis and processing of dying tumor cells. They have been used in different clinical settings to vaccinate cancer patients. We have prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d15097f8a5e17043e8aa92df44859b6c
https://doi.org/10.1371/journal.pone.0040311
https://doi.org/10.1371/journal.pone.0040311
Publikováno v:
Scopus-Elsevier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e53f7caa91eaf76018efc27e2ceb70e
https://doi.org/10.1016/j.biopha.2008.07.066
https://doi.org/10.1016/j.biopha.2008.07.066
Autor:
María Marcela Barrio, Riad Abes, Marina Colombo, Gabriela Pizzurro, Charlotte Boix, María Paula Roberti, Emmanuelle Gélizé, Mariana Rodriguez-Zubieta, José Mordoh, Jean-Luc Teillaud
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e40311 (2012)
Dendritic cells (DC) can achieve cross-presentation of naturally-occurring tumor-associated antigens after phagocytosis and processing of dying tumor cells. They have been used in different clinical settings to vaccinate cancer patients. We have prev
Externí odkaz:
https://doaj.org/article/6063186d4c954a6191316ff2f4298ff8